Biomarker and target solutions: bespoke models for drug developers
Custom biomarker models
Models built for proprietary biomarkers, with a clear path to the clinic
Approach
Build
A proof of concept on archived tissue, validated against pathologist scores and across sites and scanners.
Qualify
Run retrospectively on clinical trial samples and test against patient outcomes to build the evidence dossier.
Deploy
Used in the clinic as a laboratory-developed test or regulated diagnostic, including companion diagnostics.
Example use cases
Scoring hard-to-read IHC biomarkers
Our 50+ models automatically score IHC stains that are hard to read consistently by eye, including for ADCs and radiopharmaceuticals. Models locate staining by cell compartment, grade intensity, and calculate scores such as TPS and CPS.
F1 > 0.95
Positive vs. negative scoring of proprietary biomarkers, >0.85 multiclass
F1: agreement with reference scores, 1 is perfect. Source: Aignostics internal analyses
Predicting molecular status from routine H&E
Trained on H&E slides paired with IHC and gene panel results, our models predict biomarker expression and mutation status from H&E alone. Validated models can pre-screen patients for trials or serve as diagnostics.
AUC 0.86
Biomarker expression vs. pathologist scores. 0.94 with clinical data added
AUC: 0.5 is chance, 1 is perfect. Source: Aignostics internal analyses
Target and biomarker identification
Uncover new biology with multimodal data and AI
Aignostics approach
In partnership with Bayer, we developed a platform that assesses novel targets and biomarkers across clinical, spatial, and omics data, fusing insights from multiple levels of biology, including:
- Clinical metadata
- H&E / IHC
- mIF
- Spatial transcriptomics
- Proteomics
- scRNA-seq
- Methylomics

Inquire about biomarker and target solutions
Fill out the form to discuss custom biomarker models or target and biomarker identification.